( April 30, 2025, 4:17 PM EDT) -- FORT WORTH, Texas — A Texas federal judge on April 29 set a briefing schedule for motions for summary judgment in a dispute over the U.S. Food and Drug Administration’s removal of semaglutide, an FDA-approved drug for diabetes and weight loss, from the agency’s drug shortage list after the judge denied a motion for a preliminary injunction and a stay filed by a drug compounder and an association representing the interests of drug compounders....